HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Mirtazapine
Mirtazapine Anhydrous · REMERON · Mirtazapin · MIRTAZEPINE · Mirtazapine CRS · ZISPIN · ORG-3770 · MIRTAZAPINE
Identifikatoren & physikalische Daten
| CAS No. | 61337-67-5 |
|---|---|
| Summenformel | C17H19N3 |
| Durchschnittliche Molmasse | 265,35 g/mol |
| Monoisotopische Masse | 265,15789761 g/mol |
| SMILES | CN1CCN2c3ncccc3Cc3ccccc3C2C1 |
| InChIKey | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| PubChem CID | 4205 |
| ChEMBL | CHEMBL654 |
| ChEBI | CHEBI:6950 |
| EC No. | 288-060-6 |
| DTXSID | DTXSID0023325 |
Chemische & physikalische Eigenschaften
| XLogP | 3,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 19,4 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 0 |
| Schwere Atome | 20 |
| Formalladung | 0 |
| Komplexität | 345 |
| Arzneimittel | DEA NFLIS-Drug Category -> AntidepressantsPharmaceuticalsPharmaceuticals -> Used in SwitzerlandPharmaceuticals -> Tetracyclic Antidepressants (TeCAs) |
| LogP (Verteilungskoeffizient) | 2.92.82 |
| Löslichkeit | slightly soluble in water1.10e+00 g/LDMSO: ~8 mg/mL, soluble |
| Human Drugs | Breast FeedingLactationMilk, HumanAntidepressive AgentsAntidepressive Agents, Second-GenerationAdrenergic alpha-2 Receptor AntagonistsSerotonin 5-HT2 Receptor AntagonistsSerotonin 5-HT3 Receptor AntagonistsFDA approved drugs -> Active ingredientPharmaceuticals |
| Animal Drugs | EMA approved medicines: Veterinary medicineActive Ingredients (Mirtazapine) -> FDA Greenbook |
| Schmelzpunkt | 114-116 °C114 - 116 °C114-116°C |
| Physical Description | Solid |
| Dissociation Constants | 7.37.7 |
| Collision Cross Section | 161 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| Siedepunkt | 432.4±45.0 °C(Predicted) |
| Dichte | 1.22±0.1 g/cm3(Predicted) |
| Flammpunkt | 9°C |
| Lagerbedingungen | 2-8°C |
| Aggregatzustand | solid |
| pKa (Säurekonstante) | 8.10±0.20(Predicted) |
| Farbe | white |
| BCS Class | 1 |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 |
| InChIKey | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| SMILES | N12CCN(C)CC1C1=CC=CC=C1CC1=CC=CN=C21 |
| CAS Datenbank | 85650-52-8(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P270, P271, P273, P280, P301+P317, P304+P340, P318, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 60 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Mirtazapine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Treatment | Treatment should consist of those general measures employed in the management of overdose with any drug effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hemoperfusion or exchange transfusion in the treatment of mirtazapine overdosage. No specific antidotes for mirtazapine are known. (L1712) |
| Hepatotoxicity | Liver test abnormalities have been reported to occur in up to 10% of patients on mirtazapine, but elevations are usually modest and rarely require dose modification or discontinuation. Rare instances of acute, clinically apparent episodes of liver injury with marked liver enzyme elevations with or without jaundice have been reported in patients on mirtazapine. The onset of injury has varied greatly from several months to several years. The pattern of serum enzyme elevations is usually hepatocellular, but mixed forms have also been described. Autoimmune (autoantibodies) and immunoallergic features (rash, fever, eosinophilia) are uncommon. |
| Unerwünschte Wirkungen | Mirtazapine has several significant side effects. The adverse effects known to occur in >10% of patients receiving this drug are listed below. |
| Expositionspfade |
Anwendungen & Verwendung
Verwenden
Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. Mirtazapine (Remeron, Avanza) used primarily in the treatment of depression. It is also sometimes used as a hypnotic, antiemetic, and appetite stimulant, and for the treatment of anxiet